5 hours ago
1
fadfebrian
LB Pharmaceuticals (LBRX), a drug developer focused on neuropsychiatric diseases has announced terms for its initial public offering on Nasdaq seeking a valuation of more than $300M according to a regulatory filing.
The New York-based biopharma plans to offer roughly
English (US) ·